Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.62 |
| ▸ | BRAF | P15056 | 12/20 | 0.56 |
| ▸ | RAF1 | P04049 | 7/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | PLK4 | O00444 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.51 |
| ▸ | FYN | P06241 | 2/20 | 0.51 |
| ▸ | LYN | P07948 | 2/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.51 |
| ▸ | FRK | P42685 | 2/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12355381 | 0.89 | KDR (0.59) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL618015 | 0.89 | KDR (0.59) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL4371903 | 0.89 | KDR (0.59) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL6387865 | 0.88 | KDR (0.61) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL30078261 | 0.88 | KDR (0.61) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL29396481 | 0.88 | KDR (0.58) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL6385161 | 0.88 | KDR (0.58) | KDRBRAFRAF1EPHX2CSF1R | |
| Hydrochloric Acid SCHEMBL621069 | 0.88 | KDR (0.58) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL1219701 | 0.88 | KDR (0.58) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL619670 | 0.88 | KDR (0.58) | KDRBRAFRAF1EPHX2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614330-B2 | Substituted benz-azoles and methods of their use as inhibitors of RAF kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| EP-1957078-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC (US) | 2013-08-28 | — | — | EP | disclosed |
| EP-1608369-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2258365-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8338594-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8299108-B2 | for treatment of hematological/hormone-dependent cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-7893096-B2 | For example, N-methyl-4-[(2-{[2-(1-methylethyl)phenyl]amino}-1 H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide; administering the compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2258365-A1 | Use of organic compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2004092360-A2 | THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | CHIRON CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | KDR 1078/4885BRAF 1/4885RAF1 2/4885 |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | KDR 891/4885BRAF 1/4885RAF1 2/4885 |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | KDR 1078/4885BRAF 1/4885RAF1 2/4885 |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | KDR 83/4885BRAF 612/4885RAF1 1846/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | KDR 4021/4885BRAF 1513/4885RAF1 2839/4885 |
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | AURKC, AURKA, PLK1 | KDR 1946/4885BRAF 739/4885RAF1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.